(S)-4-(Benzyloxy)-3-((tert-butoxycarbonyl)amino)butanoic acid, 95.0%, 250mg

Pyridine hydrobromide perbromide, 90.0%, 1g

1-(Hydroxymethyl)cyclopentane-1-carbonitrile, 97%, 100mg

1-Bromo-4-iodo-5-methyl-2-nitrobenzene, 97%, 250mg

1-(4-Acetylpiperazin-1-yl)-2-(4-nitrophenyl)ethan-1-one, 97%, 1g

1-(Pyridin-2-yl)-1,4-diazepane, 98.0%, 1g

Microliter syringe GASTIGHT® series 1700 Point type 2, 25 µl, 1702 RN, 1 piece

3,5-Dichloro-4-hydroxybenzonitrile, 97.0%, 5g

2-BOC-1,2,3,4-TETRAHYDROISOQUINOLINE-6-CARBALDEHYDE, 95.0%, 250mg

Methyl 3-Chloropyrazine-2-carboxylate, 97.0%, 10g

5-Fluorobenzo[c][1,2]oxaborol-1(3H)-ol, 98.0%, 1g

2-Amino-N-(tert-butyl)-2-methylpropanamide hydrochloride, 95%, 1g

Nickel foil 99.99% 1 x 100 x 200 mm 1 pc